IP Library Granted Patent US 10,959,990
Granted Patent B2
US 10,959,990 · App. 16/881,570 · Granted Mar 30, 2021

Compositions and methods for the treatment of presbyopia

Inventor: Gerald Horn (Deerfield, IL)
Assignee: PRESBYOPIA THERAPIES, INC
A61K31/439A61K31/4409A61K47/10A61K47/12A61K47/183A61K47/26A61K47/38A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,959,990
App. No.
16/881,570
Granted
Mar 30, 2021
Kind
B2
Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions comprise aceclidine hydrochloride, polysorbate 80, mannitol, anhydrous hypromellose, disodium edetate dihydrate, benzalkonium chloride, sorbic acid and anhydrous sodium citrate and optionally tropicamide.

Claims (12)

1. A composition for the treatment of presbyopia comprising about 1.75% w/w aceclidine hydrochloride, about 4.0% w/w polysorbate 80, about 2.5% w/w mannitol, about 1.25% w/w anhydrous hypromellose, about 0.1% w/w disodium edetate dihydrate, about 0.02% w/w benzalkonium chloride, about 0.12% w/w sorbic acid and about 0.077% w/w anhydrous sodium citrate, wherein w/w denotes weight by total weight of the composition and wherein the composition has a pH of about 5.0.

2. The composition of claim 1 , further comprising about 0.01% w/w tropicamide.

3. A composition for the treatment of presbyopia comprising about 1.75% w/w aceclidine hydrochloride, about 4.0% w/w polysorbate 80, about 2.5% w/w mannitol, about 1.25% w/w anhydrous hypromellose, about 0.1% w/w disodium edetate dihydrate, about 0.02% w/w benzalkonium chloride, about 0.12% w/w sorbic acid and about 0.1% w/w anhydrous sodium citrate, wherein w/w denotes weight by total weight volume of the composition and wherein the composition has a pH of about 5.0.

4. A composition for the treatment of presbyopia comprising about 1.75% w/w aceclidine hydrochloride, about 0.01% w/w tropicamide, about 4.0% w/w polysorbate 80, about 2.5% w/w mannitol, about 1.25% w/w anhydrous hypromellose, about 0.1% w/w disodium edetate dihydrate, about 0.02% w/w benzalkonium chloride, about 0.12% w/w sorbic acid and about 0.1% w/w anhydrous sodium citrate, wherein w/w denotes weight by total weight of the composition and wherein the composition has a pH of about 5.0.

5. A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

6. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

7. A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 2 .

8. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 2 .

9. A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 3 .

10. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 3 .

11. A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 4 .

12. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 4 .

Assignments (4)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
CHANGE OF NAME Recorded Dec 15, 2022
From: PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 062138/0206 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: HORN, GERALD; NORDAN, LEE
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052849/0632 →
Continuity (14)
Continuation In Part 16106730 · Aug 21, 2018
Continuation In Part 15956936 · Apr 19, 2018
Continuation In Part 15864703 · Jan 8, 2018
Continuation In Part 15235431 · Aug 12, 2016
Continuation In Part 15073089 · Mar 17, 2016
Continuation In Part 15073089 · Mar 17, 2016
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 14223639 · Mar 24, 2014
Provisional Application 61938438 · Feb 11, 2014
Provisional Application 61917620 · Dec 18, 2013
Provisional Application 61904510 · Nov 15, 2013
Provisional Application 61882998 · Sep 26, 2013
Provisional Application 61871215 · Aug 28, 2013
Related Publication 20200281906A1 · Sep 10, 2020
Cited By (3)
US 12,414,942 US 12,533,347 US 12,653,779